Cargando…
Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
Autores principales: | Zhang, Peitao, Guan, Haixia, Yuan, Shukai, Cheng, Huili, Zheng, Jian, Zhang, Zhenlei, Liu, Yifan, Yu, Yang, Meng, Zhaowei, Zheng, Xiangqian, Zhao, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671907/ https://www.ncbi.nlm.nih.gov/pubmed/36396645 http://dx.doi.org/10.1038/s41467-022-34545-6 |
Ejemplares similares
-
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
por: Zhang, Peitao, et al.
Publicado: (2022) -
Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015) -
Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
por: Chen, Jianhua, et al.
Publicado: (2023) -
Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013) -
Author Correction: Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis
por: Liu, Shujing, et al.
Publicado: (2019)